Compare CBLI to:
After Hours: 0.00 N/A (N/A) 7:00pm ET
| Last Trade: | 3.36 |
|---|---|
| Trade Time: | 4:00pm ET |
| Change: | |
| Prev Close: | 3.42 |
| Open: | 3.40 |
| Bid: | 2.85 x 100 |
| Ask: | 5.99 x 500 |
| 1y Target Est: | 10.50 |
| Day's Range: | 3.35 - 3.50 |
|---|---|
| 52wk Range: | 1.15 - 6.35 |
| Volume: | 84,674 |
| Avg Vol (3m): | 96,538.5 |
| Market Cap: | 67.63M |
| P/E (ttm): | N/A |
| EPS (ttm): | -1.28 |
| Div & Yield: | N/A (N/A) |
| Tue 8:30am | Cleveland BioLabs President and CEO Reports Progress on Clinical and Corporate DevelopmentsMarketwire |
| Mon, Nov 23 | Cleveland BioLabs Opens Enrollment of Second Safety Study for CBLB502Marketwire |
| Wed, Nov 18 | Cleveland BioLabs Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical PotentialMarketwire |
| Wed, Nov 18 | CLEVELAND BIOLABS INC FinancialsEDGAR Online Financials |
| Thu, Nov 12 | CLEVELAND BIOLABS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online |
| Mon, Nov 2 | Cleveland BioLabs to Present at Merriman 6th Annual Investor SummitMarketwire |
| Tue, Oct 20 | Cleveland BioLabs to Host Roundtable on Protectan CBLB502 for Acute Radiation SyndromeMarketwire |
| Mon, Oct 19 | Cleveland BioLabs to Present at 8th Annual BIO Investor ForumMarketwire |
| Tue, Oct 6 | Department of Defense Increases Ongoing Contract With Cleveland BioLabs for Developmental Studies Related to Protectan CBLB502Marketwire |
| Mon, Oct 5 | Rodman & Renshaw Initiates Analyst Coverage of Cleveland BioLabsMarketwire |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.